Investing
Coherus BioSciences surges on FDA Udenyca delivery system approval
© Reuters. Coherus BioSciences (CHRS) surges on FDA Udenyca delivery system approval
Shares of Coherus BioSciences (CHRS) surged 35% in premarket trading on Wednesday after the company announced the U.S. Food and Drug Administration (FDA) approved its UDENYCA ONBODY product.
UDENYCA ONBODY is the company’s on-body injector (OBI) presentation of UDENCYA, designed for a five-minute injection time. The device features an automatic retractable needle mechanism.
“The on-body injector for UDENYCA is the result of years of significant investment in research and development to bring forward a novel and proprietary device that provides patients with an automatic delivery option for their medication,” said Denny Lanfear, CEO of Coherus.
Paul Reider, Coherus’s chief commercial officer, said: “Our market studies showed a significant demand for a novel on-body pegfilgrastim delivery device tailored to specific patient needs. We expect that UDENYCA ONBODY’s five-minute injection time and innovative retractable needle mechanism will be well received by cancer patients, their caregivers, and doctors.”
Coherus said it conducted extensive market research, revealing a strong demand for the system.
The company’s shares are trading just below the $3 per share mark ahead of Wednesday’s open.
Read the full article here
-
Side Hustles6 days ago
How to Develop Empowered Leaders Within Your Own Team
-
Side Hustles4 days ago
How to Be Unapologetically You and Why It Matters
-
Passive Income5 days ago
Are You Running Your Business, or Is Your Business Running You?
-
Investing5 days ago
7 Marketing Strategies to Help Your Startup Grow and Scale
-
Side Hustles5 days ago
How Your Body Language Can Help Win a Disagreement
-
Side Hustles6 days ago
Why the Best Time to Sell Your Business Is When You Least Expect It
-
Side Hustles5 days ago
OpenAI Raises Record $6.6 Billion, Adds 50 Million New Users
-
Make Money5 days ago
FlexJobs Report: Here’s How Workers View AI and Job Stability